Platensimycin and platencin are novel antibiotics produced by Streptomyces platensis. They are potent and non-toxic natural products active against Gram-positive pathogens, including antibiotic-resistant strains and Mycobacterium tuberculosis. They were isolated using an intriguing target-based whole-cell antisense differential sensitivity assay as inhibitors of fatty acid biosynthesis of type II. This type of biosynthesis is not present in humans. Platensimycin inhibits the elongation-condensing enzyme FabF, whereas platencin inhibits both FabF and FabH. For these antibiotics to become successful drugs, their pharmacokinetics must be improved. They have too high a rate of clearance in the body, yielding a low degree of systematic exposure. They work well when administered by continuous infusion, but this is not a useful method of delivery to patients. The two antibiotics and many analogs have been prepared by chemical synthesis. Natural congeners have also been obtained from the producing actinomycete. However, none of these molecules are as active as platensimycin and platencin. Using tools of rational metabolic engineering, superior strains have been produced making hundreds of times more antibiotic than the natural strains.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1038/ja.2011.80 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Asymmetric Synthesis and Biological Evaluation of Platensilin, Platensimycin, Platencin, and Their Analogs via a Bioinspired Skeletal Reconstruction Approach.
J Am Chem Soc
July 2024
Department of Natural Products Chemistry, Key Laboratory of Chemical Biology, School of Pharmaceutical Sciences, Shandong University, No. 44, Wenhuaxi Rd, Jinan 250012, P. R. China.
Platensilin, platensimycin, and platencin are potent inhibitors of β-ketoacyl-acyl carrier protein synthase (FabF) in the bacterial and mammalian fatty acid synthesis system, presenting promising drug leads for both antibacterial and antidiabetic therapies. Herein, a bioinspired skeleton reconstruction approach is reported, which enables the unified synthesis of these three natural FabF inhibitors and their skeletally diverse analogs, all stemming from a common -pimarane core. The synthesis features a diastereoselective biocatalytic reduction and an intermolecular Diels-Alder reaction to prepare the common -pimarane core.
View Article and Find Full Text PDFDevelopment of platensimycin, platencin, and platensilin overproducers by biosynthetic pathway engineering and fermentation medium optimization.
J Ind Microbiol Biotechnol
January 2024
D epartment of Chemistry, The Herbert Wertheim UF Scripps Institute for Biomedical Innovation & Technology, University of Florida, Jupiter, FL 33458, USA.
Article Synopsis
- The study introduces a CRISPR-Cas9 system in Streptomyces platensis to simplify the manipulation of biosynthesis for natural products like platensimycin, platencin, and platensilin.
- The researchers created designer recombinant strains (SB12051, SB12052, SB12053) that achieved high production levels of these compounds during fermentation in a specialized medium.
- The discovery of distinct chemistries from specific diterpene synthases and the development of a mutant strain (SB12054) suggests new avenues for engineering diterpenoid biosynthesis in the future.
Computational Study of the C5-Hydroxylation Mechanism Catalyzed by the Diiron Monooxygenase PtmU3 as Part of the Platensimycin Biosynthesis.
Inorg Chem
December 2021
School of Chemistry and Chemical Engineering, Shandong University, Jinan 250100, Shandong, China.
PtmU3 is a newly identified nonheme diiron monooxygenase, which installs a C-5 β-hydroxyl group into the C-19 CoA-ester intermediate involved in the biosynthesis of unique diterpene-derived scaffolds of platensimycin and platencin. PtmU3 possesses a noncanonical diiron active site architecture of a saturated six-coordinate iron center and lacks the μ-oxo bridge. Although the hydroxylation process is a simple reaction for nonheme mononuclear iron-dependent enzymes, how PtmU3 employs the diiron center to catalyze the H-abstraction and OH-rebound is still unknown.
View Article and Find Full Text PDFRapid, Selective, and Sensitive Method for Semitargeted Discovery of Congeneric Natural Products by Liquid Chromatography Tandem Mass Spectrometry.
J Nat Prod
March 2021
Merck Research Laboratories, Rahway, Kenilworth, New Jersey 07033, United States.
Article Synopsis
- Natural product congeners can help us understand how natural products are made and how they work in terms of medicinal chemistry.
- A new method using liquid-chromatography tandem-mass spectrometry has been developed to quickly and accurately discover specific congeners of platensimycin and platencin from various sources.
- This method not only confirmed known congeners but also identified many previously unknown ones, allowing for more efficient discovery in complex natural product mixtures.
Divergent synthesis of complex diterpenes through a hybrid oxidative approach.
Science
August 2020
Department of Chemistry, The Scripps Research Institute, Jupiter, FL 33458, USA.
Polycyclic diterpenes exhibit many important biological activities, but de novo synthetic access to these molecules is highly challenging because of their structural complexity. Semisynthetic access has also been limited by the lack of chemical tools for scaffold modifications. We report a chemoenzymatic platform to access highly oxidized diterpenes by a hybrid oxidative approach that strategically combines chemical and enzymatic oxidation methods.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!